News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: China's I-Mab Stages $104 Million Nasdaq IPO
I-Mab, a Shanghai biotech, raised $104 million in its IPO on the Nasdaq exchange to support its portfolio of biologic products.The offering was priced at $14 per ADS but the price has moved 10% lower to $12.58 in initial trading.
Read
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
Read
Week In Review: Shanghai's I-Mab Plans $100 Million NASDAQ IPO On January 16
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.
Read
Week In Review: Geneseeq And Elpiscience Close $100 Million VC Rounds; Zai Lab's PARP Inhibitor Approved For China Use
Geneseeq, a Nanjing-Toronto company offering genetic sequencing tests for cancer, completed a $114 million Series D financing led by China Reform Holdings Corporation. Geneseeq uses next-gen sequencing to provide decision-making tools for doctors.
Read
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.
Read
Week In Review: AlphaMab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session
Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. The company has a PD-L1 candidate that could be approved in China in 2020 and two bispecifics in Phase II tests.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications